Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Protagen AG. (1/8/15). "Press Release: Protagen AG Appoints Bernhard Kirschbaum as New Board Member". Dortmund.

Organisations Organisation Protagen AG
  Group Protagen (Group)
  Organisation 2 Merck Serono (division of Merck KGaA)
  Group Merck (DE) (Group)
Products Product companion diagnostic test
  Product 2 clinical proteomic test
  Index term 2 Qiagen–Protagen: proteomic companion diagnostics, 201410– collab €na developm for autoimmune therapies using SeroTag platform
Persons Person Kirschbaum, Bernhard (Merck Serono 200809 Executive VP Research)
  Person 2 Müllner, Stefan (Fundamenta Life-Sciences GmbH 201711 General Manager + Partner before Protagen –201610 CEO)

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics (CDx) in the autoimmune field, today announced that the former Head of Research and Early Development of Merck Serono, Dr. Bernhard Kirschbaum, has joined the company’s Supervisory Board.

This news follows the recently announced strategic partnership between Protagen and Qiagen, which will focus on pharma collaborations in the autoimmune space, an area where Dr. Kirschbaum has significant expertise.

Dr. Kirschbaum has served in executive positions at Hoechst, Aventis, Sanofi, and Merck Serono, and has a proven track record in preclinical and clinical R&D, with a special focus on autoimmune diseases and chronic inflammatory disorders. According to Dr. Kirschbaum, “Protagen offers a very solid, unique technology with broad application potential. It is of particular relevance for translational research, which remains a central topic in drug development. In many diseases, analyses at the protein level offer key insights and guidance on diseases status and drug development.”

Stefan Müllner, CEO of Protagen, added: “In order to become the leading provider of CDx for autoimmune therapy, it is imperative that we have meaningful insight into the R&D processes and interfaces of big pharma. The profound expertise Dr. Kirschbaum will bring to this role will provide us with valuable guidance, which will enable us to effectively expand our business within the growing CDx field.”

About Protagen – Diagnostics Differentiated

Protagen AG, headquartered in Dortmund, Germany, specializes in the development of novel diagnostic and companion diagnostic tests to provide better and earlier diagnosis of autoimmune diseases.

Protagen uses its proprietary SeroTag biomarker platform to identify disease specific autoantibodies and is on target to become the leading provider of autoimmune diagnostic products, specifically targeting diseases with an unmet need for effective diagnostics.

With pioneering bioscience techniques, extensive scientific expertise and a broad patent portfolio, Protagen
works to develop its own diagnostic pipeline and partners with other organizations to develop and implement
new companion diagnostic tools for better personalized treatment strategies.

For more information, please visit

Ref: PROT001/15
Release Date: 8th January 2015


Dr. Stefan Müllner
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
T +49 231 9742 6300
F +49 231 9742 6301

Media Enquiries:

Dr. Clare Russell
Managing Director
TM+44 1223 828200
MT+44 7812 343412

Record changed: 2017-04-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Protagen (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top